AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2611360 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen without Maalox (antacid)
Number of subjects: 19
Study 577520 — intervention group
Group type: EXPERIMENTAL
Intervention: Duck embryo rabies vaccine (DEV)
Number of subjects: 92
Study 577520 — intervention group
Group type: EXPERIMENTAL
Intervention: Duck embryo rabies vaccine purified by ultracentrifugation (P-DEV)
Number of subjects: 92
Study 31472438 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT) using Aldestein RTOG regimen
Number of subjects: 0
Study 31472438 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by Cetuximab radiation (IBRT)
Number of subjects: 0
Study 31472438 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival comparison
Number of subjects: 0
Study 31472438 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection quality
Number of subjects: 0
Study 28282099 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle-resolved Raman spectroscopy on TiS3, ZrS3, and HfS3
Number of subjects: 0
Study 28282099 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle-resolved studies on TiNbS3 TMTC alloy
Number of subjects: 0
Study 25805608 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC 50/100 µg delivered via Rotacaps(®)/Rotahaler(®)
Number of subjects: 0
Study 25805608 — intervention group
Group type: COMPARATOR
Intervention: SFC 50/100 µg delivered via Diskus(®)
Number of subjects: 0
Study 24167545 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ferritin
Number of subjects: 423
Study 24167545 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum transferrin receptor (sTfR)
Number of subjects: 423
Study 24167545 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 423
Study 24167545 — intervention group
Group type: EXPERIMENTAL
Intervention: Total and uncarboxylated osteocalcin
Number of subjects: 423
Study 21415046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) with fluoxetine if indicated, 20 sessions over 18 weeks
Number of subjects: 293
Study 21415046 — intervention group
Group type: COMPARATOR
Intervention: Stepped-care approach starting with supervised self-help, with fluoxetine added if non-responders after 6 sessions, followed by CBT if needed
Number of subjects: 293
Study 19011153 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) with supervised lifestyle counseling
Number of subjects: 72
Study 19011153 — intervention group
Group type: COMPARATOR
Intervention: Routine lifestyle counseling
Number of subjects: 72
Study 17398182 — intervention group
Group type: EXPERIMENTAL
Intervention: FilterWire EZ
Number of subjects: 100
Study 17398182 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular guidewires)
Number of subjects: 100
Study 14716714 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (four 3 mg dextrose tablets)
Number of subjects: 75
Study 14716714 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sorbitol tablets)
Number of subjects: 75
Study 11511119 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-fluoro-2-deoxyglucose (FDG) positron emission tomography during a standardized euglycaemic hyperinsulinaemic glucose clamp
Number of subjects: 178
Study 11511119 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative improvement in ejection fraction
Number of subjects: 178
Study 9581743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (1 mg IV infusion, two 10-min infusions)
Number of subjects: 127
Study 9581743 — intervention group
Group type: COMPARATOR
Intervention: Procainamide (400 mg IV infusion, three successive 10-min infusions)
Number of subjects: 127
Study 9581743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (in atrial flutter subgroup)
Number of subjects: 127
Study 9581743 — intervention group
Group type: COMPARATOR
Intervention: Procainamide (in atrial flutter subgroup)
Number of subjects: 127
Study 9581743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (in atrial fibrillation subgroup)
Number of subjects: 127
Study 9581743 — intervention group
Group type: COMPARATOR
Intervention: Procainamide (in atrial fibrillation subgroup)
Number of subjects: 127
Study 9581743 — intervention group
Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 127
Study 9581743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 127
Study 9048272 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg/day
Number of subjects: 208
Study 9048272 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg/day
Number of subjects: 208
Study 9048272 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day
Number of subjects: 208
Study 9048272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 9048272 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 208
Study 1937372 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (30 mg taken as a single morning dose)
Number of subjects: 143
Study 1937372 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (400 mg b.i.d.)
Number of subjects: 143
Study 1937372 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 143
Study 1937372 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 143
Study 1937372 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 143
Study 6310075 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral oil
Number of subjects: 37
Study 6310075 — intervention group
Group type: COMPARATOR
Intervention: Senokot (standardized senna concentrate)
Number of subjects: 37
Study 31937335 — intervention group
Group type: EXPERIMENTAL
Intervention: Compatible acupoints group
Number of subjects: 216
Study 31937335 — intervention group
Group type: EXPERIMENTAL
Intervention: Single acupoint group
Number of subjects: 216
Study 31937335 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture group
Number of subjects: 216
Study 31937335 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 216
Study 31537697 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years surveillance with annual sputum samples for cytology and cytometry, followed by annual LDCT and autofluorescence bronchoscopy (AFB) if abnormal.
Number of subjects: 1568
Study 31537697 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 1568
Study 31537697 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum cytology/cytometry.
Number of subjects: 1568
Study 31537697 — intervention group
Group type: EXPERIMENTAL
Intervention: AFB for sputum-positive individuals.
Number of subjects: 1568
Study 31537697 — intervention group
Group type: EXPERIMENTAL
Intervention: LDCT for sputum-positive individuals.
Number of subjects: 1568
Study 27654637 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAMS therapy
Number of subjects: 14
Study 27882838 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Pharmacy Care (EPC)
Number of subjects: 1002
Study 27882838 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1002
Study 23785050 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg bolus intravenously 10 to 15 minutes before procedure, followed by 40 mg once daily for 7 days in low-risk group.
Number of subjects: 184
Study 23785050 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg bolus intravenously 10 to 15 minutes before procedure, followed by 1 mg/kg subcutaneously 2 times a day for 48 hours, then 40 mg once daily for 5 days in high-risk group.
Number of subjects: 184
Study 21899708 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaseline (n = 49)
Number of subjects: 146
Study 21899708 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel (n = 51)
Number of subjects: 146
Study 21899708 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% lidocaine plus 2.5% prilocaine cream (n = 46)
Number of subjects: 146
Study 20169261 — intervention group
Group type: EXPERIMENTAL
Intervention: LTS-D (disposable laryngeal tube suction)
Number of subjects: 60
Study 20169261 — intervention group
Group type: COMPARATOR
Intervention: LTS-II (reusable laryngeal tube suction)
Number of subjects: 60
Study 18779616 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate, 1.6 g orally administered daily
Number of subjects: 268
Study 18779616 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study 15721693 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK (n=25; mean SER -7.12 D ± 0.57 [SD])
Number of subjects: 45
Study 15721693 — intervention group
Group type: COMPARATOR
Intervention: PRK (n=20; mean SER -6.91 ± 0.57 D)
Number of subjects: 45
Study 15721693 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 45
Study 15721693 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 45
Study 15721693 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK and PRK
Number of subjects: 45
Study 12741452 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg daily for 4 weeks
Number of subjects: 223
Study 12741452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 10595816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 187
Study 10595816 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 187
Study 10595816 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-body irradiation-containing conditioning regimens
Number of subjects: 187
Study 10595816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nausea scoring system
Number of subjects: 187
Study 9373732 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha-2b (3 x 10(6) IU, 3 times weekly)
Number of subjects: 162
Study 1399377 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 55
Study 1399377 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 55
Study 2409356 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 0
Study 2409356 — intervention group
Group type: COMPARATOR
Intervention: Matched placebos
Number of subjects: 0
Study 31455384 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bed cycling intervention
Number of subjects: 256
Study 29766635 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-1293 insulin glargine (Mk-Gla; 100 U/mL)
Number of subjects: 508
Study 29766635 — intervention group
Group type: COMPARATOR
Intervention: Originator insulin glargine (Lantus; Sa-Gla)
Number of subjects: 508
Study 29766635 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-1293 insulin glargine (Mk-Gla)
Number of subjects: 508
Study 29766635 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MK-1293 and Sa-Gla
Number of subjects: 508
Study 27548031 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families Program plus Life Skills Training (SFP 10‐14 + LST)
Number of subjects: 36
Study 27548031 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Skills Training (LST) only
Number of subjects: 36
Study 27548031 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study 27548031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette frequency
Number of subjects: 36
Study 24910399 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee stabilization therapy prior to strength/functional training
Number of subjects: 159
Study 24910399 — intervention group
Group type: COMPARATOR
Intervention: Control programme (without knee stabilization therapy)
Number of subjects: 159
Study 21954229 — intervention group
Group type: EXPERIMENTAL
Intervention: WGET intervention group
Number of subjects: 417
Study 21954229 — intervention group
Group type: EXPERIMENTAL
Intervention: VCRC-LS intervention group
Number of subjects: 417
Study 19443132 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana smoked as joints (0.0, 1.8, and 3.6% THC)
Number of subjects: 24
Study 19443132 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana smoked as blunts (0.0, 1.8, and 3.6% THC)
Number of subjects: 24
Study 17160087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (4 GP consultations over 12 weeks)
Number of subjects: 163
Study 17160087 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 163
Study 15580176 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary caregivers
Number of subjects: 75
Study 15580176 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 75
Study 11428474 — intervention group
Group type: EXPERIMENTAL
Intervention: Lone atrial fibrillation with embolic stroke
Number of subjects: 0
Study 11428474 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemispheric dominance
Number of subjects: 0
Study 11428474 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemispheric dominance
Number of subjects: 0
Study 8288727 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg bid)
Number of subjects: 52
Study 8288727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 3553111 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (XRT) - 50 Gy in 20 fractions to the kidney bed and regional lymph nodes
Number of subjects: 65
Study 3553111 — intervention group
Group type: COMPARATOR
Intervention: Observation (no further treatment)
Number of subjects: 65
Study 30166301 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36
Study 30166301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 27486878 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy (docetaxel, cisplatin, and fluorouracil)
Number of subjects: 278
Study 27486878 — intervention group
Group type: COMPARATOR
Intervention: PF induction chemotherapy (cisplatin and fluorouracil)
Number of subjects: 278
Study 27486878 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Number of subjects: 278
Study 27486878 — intervention group
Group type: COMPARATOR
Intervention: PF induction chemotherapy
Number of subjects: 278
Study 25602687 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligonol (200 mg daily for 1 week)
Number of subjects: 20
Study 24200273 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure-using group
Number of subjects: 100
Study 24200273 — intervention group
Group type: COMPARATOR
Intervention: Non-using group
Number of subjects: 100
Study 21167471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 500 mg twice daily
Number of subjects: 593
Study 21167471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 1 g twice daily
Number of subjects: 593
Study 21167471 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 500 mg twice daily
Number of subjects: 593
Study 18482424 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent voucher condition
Number of subjects: 82
Study 18482424 — intervention group
Group type: COMPARATOR
Intervention: Non-contingent voucher condition
Number of subjects: 82
Study 16939849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer inpatients
Number of subjects: 25
Study 12883767 — intervention group
Group type: EXPERIMENTAL
Intervention: Open (Bankart)
Number of subjects: 147
Study 12883767 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic (ASK)
Number of subjects: 147
Study 11719823 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized estradiol substitution (Group I)
Number of subjects: 7500
Study 11719823 — intervention group
Group type: COMPARATOR
Intervention: No estradiol substitution (Group II)
Number of subjects: 7500
Study 9123736 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant androgen deprivation therapy (ADT) with 3.6 mg goserelin for 28 days and 750 mg flutamide daily
Number of subjects: 141
Study 9123736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ADT prior to surgery)
Number of subjects: 141
Study 9123736 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant ADT (goserelin and flutamide)
Number of subjects: 141
Study 9123736 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ADT (goserelin and flutamide)
Number of subjects: 141
Study 9123736 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 141
Study 9123736 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT-treated patients
Number of subjects: 141
Study 9123736 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 141
Study 9123736 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ADT
Number of subjects: 141
Study 1362748 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin-clavulanic acid
Number of subjects: 150
Study 1362748 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 150
Study 3423732 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 34
Study 3423732 — intervention group
Group type: EXPERIMENTAL
Intervention: De‐Nol
Number of subjects: 34
Study 3423732 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox 70
Number of subjects: 34
Study 3423732 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate, De‐Nol, and Maalox 70
Number of subjects: 34
Study 3423732 — intervention group
Group type: COMPARATOR
Intervention: atropine
Number of subjects: 34
Study 3423732 — intervention group
Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 34
Study 3423732 — intervention group
Group type: COMPARATOR
Intervention: pirenzepine
Number of subjects: 34
Study 30465070 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 332
Study 30465070 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 332
Study 27776246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch wear time during the first week post-quit
Number of subjects: 74
Study 27776246 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing the patch for ≥19h
Number of subjects: 74
Study 26283275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg once daily
Number of subjects: 71
Study 26283275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 24035889 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete free choice
Number of subjects: 288
Study 24035889 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing choice
Number of subjects: 288
Study 24035889 — intervention group
Group type: COMPARATOR
Intervention: Explaining relevance
Number of subjects: 288
Study 22269666 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized 311-nm narrow-band ultraviolet B (NB-UVB)
Number of subjects: 11
Study 22269666 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm monochromatic excimer light (MEL)
Number of subjects: 11
Study 22269666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 19143914 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil treatment (flexible-dose or fixed-dose)
Number of subjects: 1296
Study 19143914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1296
Study 16715674 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g iodine
Number of subjects: 66
Study 16715674 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 g iodine
Number of subjects: 66
Study 16715674 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g iodine
Number of subjects: 66
Study 14754790 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg)
Number of subjects: 10
Study 14754790 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 11395041 — intervention group
Group type: EXPERIMENTAL
Intervention: FH patients
Number of subjects: 51
Study 11395041 — intervention group
Group type: EXPERIMENTAL
Intervention: FH patients with vascular disease
Number of subjects: 51
Study 11395041 — intervention group
Group type: EXPERIMENTAL
Intervention: FH patients with and without vascular disease
Number of subjects: 51
Study 9243654 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine preoperative testing prior to cataract surgery
Number of subjects: 20000
Study 9243654 — intervention group
Group type: COMPARATOR
Intervention: Exclusion of second eye surgeries
Number of subjects: 20000
Study 9243654 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of first and second eyes but randomization of patients rather than eyes
Number of subjects: 20000
Study 9243654 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of first and second eyes but randomization of surgeries rather than patients
Number of subjects: 20000
Study 8299830 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed radiography with a photostimulable storage phosphor (50% radiation dose)
Number of subjects: 40
Study 8299830 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed radiography with a photostimulable storage phosphor (20% radiation dose)
Number of subjects: 40
Study 8299830 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed radiography with a photostimulable storage phosphor (10% radiation dose)
Number of subjects: 40
Study 8299830 — intervention group
Group type: COMPARATOR
Intervention: Conventional calcium tungstate screen‐film combination (100% radiation dose)
Number of subjects: 40
Study 3773621 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-channel amplitude compression hearing aid
Number of subjects: 12
Study 3773621 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-channel amplitude compression hearing aid
Number of subjects: 12
Study 3773621 — intervention group
Group type: COMPARATOR
Intervention: Personal aid
Number of subjects: 12
Study 31659595 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet (GFD)
Number of subjects: 66
Study 31659595 — intervention group
Group type: COMPARATOR
Intervention: Gluten-Containing Diet (GD)
Number of subjects: 66
Study 29879606 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25-50mg
Number of subjects: 633
Study 29879606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study 27559716 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 plus capsules
Number of subjects: 140
Study 27559716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 25266981 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable steroid-eluting implant with 1350 μg of mometasone furoate
Number of subjects: 100